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Abstract
Schizophrenia is characterised by cognitive impairments that are already present during early stages, including in the clini-
cal high-risk for psychosis (CHR-P) state and first-episode psychosis (FEP). Moreover, data suggest the presence of distinct 
cognitive subtypes during early-stage psychosis, with evidence for spared vs. impaired cognitive profiles that may be dif-
ferentially associated with symptomatic and functional outcomes. Using cluster analysis, we sought to determine whether 
cognitive subgroups were associated with clinical and functional outcomes in CHR-P individuals. Data were available for 
146 CHR-P participants of whom 122 completed a 6- and/or 12-month follow-up; 15 FEP participants; 47 participants not 
fulfilling CHR-P criteria (CHR-Ns); and 53 healthy controls (HCs). We performed hierarchical cluster analysis on principal 
components derived from neurocognitive and social cognitive measures. Within the CHR-P group, clusters were compared 
on clinical and functional variables and examined for associations with global functioning, persistent attenuated psychotic 
symptoms and transition to psychosis. Two discrete cognitive subgroups emerged across all participants: 45.9% of CHR-P 
individuals were cognitively impaired compared to 93.3% of FEP, 29.8% of CHR-N and 30.2% of HC participants. Cogni-
tively impaired CHR-P participants also had significantly poorer functioning at baseline and follow-up than their cognitively 
spared counterparts. Specifically, cluster membership predicted functional but not clinical outcome. Our findings support the 
existence of distinct cognitive subgroups in CHR-P individuals that are associated with functional outcomes, with implica-
tions for early intervention and the understanding of underlying developmental processes.
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Introduction
Schizophrenia is a debilitating psychiatric disorder char-
acterised by psychotic symptoms, including hallucinations 
and delusions, as well as impairments in cognition, sensory 
processing and psychosocial functioning [1, 2]. Cognitive 
impairments span several domains including processing 
speed, working memory, executive functions, attention 
and social cognition [3, 4]. Schizophrenia is preceded, in 
the majority of cases, by a clinical high-risk for psychosis 
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(CHR-P) state lasting approximately 5–6 years [5]. CHR-P 
status is determined using ultra-high-risk (UHR) criteria, 
encompassing attenuated psychotic symptoms (APS), brief 
frank psychosis and functional decline with genetic risk [6], 
as well as basic symptom criteria that involve self-experi-
enced perceptual and cognitive disturbances [7, 8]. CHR-P 
individuals are also characterised by widespread cognitive 
impairments intermediate between healthy controls (HC) 
and first-episode psychosis (FEP) patients [9, 10]. These 
impairments, especially in attention, working memory and 
declarative memory, are more pronounced in CHR-P indi-
viduals who later transition to psychosis [11]. However, cog-
nitive performance within the CHR-P state is highly vari-
able with small-to-large effect size impairments (Cohen’s 
d = − 0.35 to − 0.84) in those who transition to psychosis 
and small-to-medium impairments (d = − 0.26 to − 0.67) in 
those who do not [9]. Accordingly, novel approaches may be 
required to identify subtypes of CHR-P participants with dif-
ferent cognitive profiles, with possible implications for the 
understanding of underlying pathophysiology and accurate 
prediction of outcomes.
Data-driven approaches, such as cluster analysis, classify 
individuals according to levels and patterns of performance, 
rather than pre-determined grouping criteria [12]. Cogni-
tive subgroups have successfully been identified in cross-
diagnostic samples, comprising individuals with schizophre-
nia-spectrum disorders or mood disorders [12–16]. These 
findings support the existence of a range of cognitive impair-
ments across different syndromes with evidence for two [14], 
three [13, 16] and four [12, 15] cognitive subgroups.
Furthermore, emerging evidence suggests that cluster 
analysis can identify phenotypes that relate more closely 
to specific clinical and functional trajectories than existing 
diagnostic categories [17]. Indeed, such approaches have 
highlighted poorer functioning and greater symptom severity 
in cognitively impaired vs. cognitively spared subgroups in 
schizophrenia-spectrum populations [12, 15, 18–21]. Moreo-
ver, subgroups with impaired cognition have also been asso-
ciated with reductions in brain volume [22, 23] and different 
profiles of treatment response [24].
There is preliminary evidence for similar profiles of 
cognitive impairment in FEP patients, with little consensus 
on the number of emergent clusters [25–28]. Wenzel et al. 
[28] and Reser et al. [25] identified two and four cognitive 
subgroups in FEP patients, respectively, with high negative 
symptom severity and low premorbid IQ characteristic of 
the most cognitively impaired subgroup. Interestingly, Uren 
et al. [27] and Sauvé et al. [26] both obtained a three-cluster 
solution and found that 28% and 54% of FEP participants, 
respectively, aggregated with HCs in the cognitively spared 
subgroup, supporting the existence of an FEP subgroup with 
intact cognitive functioning. According to Uren et al. [27], 
cluster membership was associated with symptom severity 
and functioning from baseline to 6 months, highlighting the 
potential utility of cognitive clustering for prognosis and 
early intervention.
To our knowledge, only one study has used cluster analy-
sis to examine cognitive profiles in CHR-P participants. Velt-
horst et al. [29] derived four distinct cognitive subgroups, 
whereby 44% of CHR-P participants were significantly or 
mildly impaired and 56% displayed average or above average 
cognitive scores. In addition, cognitive subgroups yielded 
prognostic information with cluster membership predicting 
conversion to psychosis over a 30-month follow-up period. 
However, this study did not examine the predictive utility 
of cognitive subgroups in relation to global functioning or 
symptom persistence and did not include any measures of 
social cognition. Furthermore, it is unclear whether these 
findings from help-seeking CHR-P participants would gener-
alise to more representative samples recruited outside clini-
cal pathways.
To address these important questions, we sought to iden-
tify cognitive clusters in a sample of CHR-P and FEP par-
ticipants, primarily recruited from the community, alongside 
individuals who did not fulfil CHR-P criteria but were char-
acterised by affective and substance use disorders (CHR-
Ns) and HCs. Specifically, we performed cluster analysis 
on principal components derived from both neurocognitive 
and social cognitive measures. We then examined the dis-
tribution of diagnostic groups across clusters and investi-
gated whether cognitive subgroups were associated with 
clinical and functional variables at baseline and follow-up 
in the CHR-P group. Given previous findings in CHR-P and 
FEP samples [25–27, 29], we hypothesised the existence 
of at least three distinct cognitive profiles. In addition, we 
expected CHR-P individuals with pronounced cognitive def-
icits to exhibit the poorest functioning and greatest symptom 
severity at baseline and follow-up as well as cluster mem-




Participants were recruited through the ongoing Youth 
Mental Health Risk and Resilience (YouR) study [30] 
which seeks to identify neurobiological and psychological 
mechanisms and predictors of psychosis risk. CHR-P par-
ticipants from the general population were recruited through 
an online-screening approach (www. your- study. org. uk) [31]. 
FEP and CHR-N participants were also recruited using this 
method while HCs were obtained from a volunteer database. 
A smaller number of CHR-P and FEP individuals were also 
recruited via referrals from clinical services in NHS Greater 
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Glasgow and Clyde and NHS Lothian as well as student 
counselling services. Ethical approval was obtained from the 
West of Scotland Research Ethics Service and the Univer-
sity of Glasgow. All participants provided written informed 
consent.
Baseline data were available for 146 CHR-P partici-
pants, 15 participants with first-episode psychosis (FEP), 
47 participants who did not fulfil CHR-P criteria (CHR-
Ns) and 53 healthy controls (HCs). Unlike HCs, CHR-N 
participants met criteria for mood and anxiety disorders as 
well as substance use. Thus, the inclusion of the CHR-N 
group allowed us to potentially disentangle the impact of 
psychiatric comorbidity from the CHR-P state since mood 
and anxiety disorders are common in this population [32]. 
Referred participants comprised 11.0% of the CHR-P sample 
and 46.7% of the FEP sample. One hundred and twenty-two 
CHR-P participants (83.6%) also completed a follow-up ses-
sion 6- and/or 12-months later.
Previous publications by our group have reported baseline 
demographic, clinical, functional and cognitive data from 
similar or smaller samples [31, 33–35].
Baseline assessments
To establish CHR-P criteria, participants received the posi-
tive scale of the Comprehensive Assessment of At-Risk 
Mental States (CAARMS) [6] and the Cognitive Distur-
bances (COGDIS) and Cognitive-Perceptive Basic Symp-
toms (COPER) items of the Schizophrenia Proneness Instru-
ment, Adult version (SPI-A) [36].
Participants were recruited into the CHR-P group if they 
met one or both SPI-A criteria (i.e. COGDIS, COPER) and/
or at least one of the following CAARMS criteria: APS, 
genetic risk and functional deterioration (GRFD), brief lim-
ited intermittent psychotic symptoms (BLIPS). FEP criteria 
were established using the Structured Clinical Interview for 
DSM-IV (SCID) [37] and the Positive and Negative Syn-
drome Scale (PANSS) [38].
Cognitive assessments consisted of the Brief Assessment 
of Cognition in Schizophrenia (BACS) [39] and three tasks 
from the Penn Computerized Neurocognitive Battery (CNB) 
[40]: the Continuous Performance Test, the N-Back Test 
and the Emotion Recognition Task which provide measures 
of accuracy and response time (RT) for attention, working 
memory and emotion recognition respectively (Supplemen-
tary Table 1). Furthermore, with the exception of the FEP 
group, all participants were assessed with the Mini-Inter-
national Neuropsychiatric Interview (MINI) [41], Global 
Assessment of Functioning (GAF) scale from the DSM-IV-
TR, Global Functioning: Social (GF: Social) and Role (GF: 
Role) scales [42], Premorbid Adjustment Scale (PAS) [43] 
and National Adult Reading Test (NART) [44].
Clinical and functional outcome
CHR-P participants were invited for follow-up interviews 
at 6- and 12-months. These involved the positive scale of 
the CAARMS as well as the GAF, GF: Social and GF: Role 
scales. Based on the most recent GAF score, CHR-P partici-
pants were divided into good functional outcome (GAF ≥ 65) 
and poor functional outcome (GAF < 65) groups, in line 
with previous research [45, 46]. CAARMS persistence was 
operationalised as meeting APS criteria at both baseline 
and the latest follow-up assessment. Transitions to psycho-
sis, recorded over a 36-month follow-up period, were also 
defined according to CAARMS criteria and subsequently 
followed up with the Structured Clinical Interview for DSM-
IV (SCID) [37] to establish the specific psychosis diagnoses.
Statistical analysis
Data were analysed using R version 4.0.1 [47] with statisti-
cal significance set at p < 0.05 (two-tailed). Overall, 0.48% 
of the data (52 of 10,904 values) were missing and imputed 
by Bayesian imputation.
In line with Keefe et  al. [48], BACS raw scores for 
each cognitive domain were converted into standardized 
z-scores using the means and standard deviations (SDs) of 
sex-specific HCs. For consistency, CNB raw accuracy and 
RT scores were calculated in the same way, albeit without 
correction for sex. RT z-scores were multiplied by − 1, to 
produce speed values where, as for accuracy, higher scores 
reflect better performance. CNB efficiency scores were then 
generated for each domain by taking the arithmetic mean of 
the accuracy and RT z-scores. Outliers beyond ± 5.0 z-scores 
were curtailed to values of + 5.0 or − 5.0. NART-derived 
estimates of premorbid full-scale IQ were obtained using a 
recently re-standardised calculation [49]. CAARMS severity 
was calculated by multiplying the global score by the fre-
quency score for each domain and summing these products 
[50] while SPI-A severity was calculated by summing the 
frequency scores for each basic symptom.
In the first step, a principal component analysis (PCA) 
was conducted on 20 cognitive tests with oblique (oblimin) 
rotation, so as to allow for possible correlations between the 
factors, using the psych [51] and GPArotation [52] pack-
ages. Data suitability for PCA was assessed with the Kai-
ser–Meyer–Olkin (KMO) measure of sampling adequacy 
[53, 54] and Bartlett's test of sphericity [55]. To determine 
the appropriate number of principle components to extract, 
we used the Kaiser criterion of eigenvalues > 1 [56] as well 
as scree plot inspection [57]. Cronbach’s α was used to deter-
mine the internal consistency of data.
In the second step, we evaluated the clustering tendency 
of our data as well as the optimal clustering approach. 
Clustering tendency of the resulting component scores was 
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assessed using the Hopkins (H) statistic via the cluster-
tend package [58]. A value close to 1 indicates uniformly 
distributed data while highly clustered data yields a value 
close to 0. To identify the optimal clustering algorithm 
and number of clusters, we used the clValid package [59] 
which simultaneously compares the different clustering 
solutions in terms of validation measures. We tested for 
the presence of two to six clusters, implementing three 
clustering methods: (1) k-means, (2) partitioning around 
medoids (PAM) and (3) agglomerative hierarchical clus-
tering. Internal validation measures were calculated as 
connectivity, silhouette width and Dunn index. Stability 
validation measures comprised the average proportion of 
non-overlap (APN), the average distance (AD), the average 
distance between means (ADM) and the figure of merit 
(FOM). Whereas internal validation measures evaluate the 
connectedness, compactness and separation of the different 
clusters, stability validation measures assess the consist-
ency of a clustering result by comparing it with the clus-
ters obtained after removing each column, one at a time. 
In general, smaller values reflect better performance, with 
the exception of silhouette width and Dunn index where 
larger values are preferable. This information was used 
to inform the third step whereby data-driven agglomera-
tive hierarchical clustering was applied to the component 
scores via the stats package [47], using Ward’s method 
and squared Euclidean distance, to produce two clusters. 
Cross-validated linear discriminant analysis, using the 
20 original standardised cognitive scores as independent 
variables, was performed with the caret package [60] to 
evaluate the classification accuracy of the final clustering 
solution.
For the CHR-P group, the resulting clusters were com-
pared on demographic, functional, clinical and cognitive 
characteristics using Welch’s t tests, Mann–Whitney U 
tests, Pearson’s chi‐squared tests and Fisher's exact tests. 
We also conducted a series of hierarchical multiple linear 
regression analyses to examine effects of cluster member-
ship on cognitive domains and functional variables after 
controlling for the potential effects of clinical (CAARMS 
and SPI-A severity) and demographic (age, sex, educa-
tion) variables to examine the possibility that differences 
by cluster were better accounted for by overall symptom 
severity or demographic characteristics. In these models, 
clinical and demographic variables were entered in step 
1 and cluster membership was entered in step 2. Binary 
logistic regression analyses were also employed to deter-
mine whether cluster membership could predict clinical 
and functional outcomes. The overall variance explained 
was measured by the Nagelkerke pseudo  R2 statistic  (R2N) 
while diagnostic accuracy was determined using the area 




CHR-P individuals had significantly fewer years of edu-
cation, greater symptom severity, higher likelihood of 
comorbid mood and anxiety disorders and poorer function-
ing compared to CHR-N and HC participants (Table 1). 
Relative to the total sample, CHR-P individuals were 
also significantly younger while FEP patients displayed 
significantly higher CAARMS severity, antipsychotic 
and anxiolytic medication use as well as poorer global 
functioning. Among the CHR-P group, 43 (29.5%) met 
CAARMS criteria, 34 (23.3%) met SPI-A criteria and 69 
(47.3%) met both. Moreover, the FEP group comprised 
participants with SCID DSM-IV schizophrenia (n = 10; 
66.7%), psychotic disorder not otherwise specified (n = 3; 
20.0%), schizoaffective disorder (n = 1; 6.7%) and schizo-
phreniform disorder (n = 1; 6.7%).
Principal component analysis
The KMO measure verified the sampling adequacy for 
the PCA (KMO = 0.70) with all values for individual 
items ≥ 0.52, which is above the acceptable limit of 0.50. 
Bartlett’s test of sphericity, χ2 (190) = 3795.385, p < 0.001, 
indicated that correlations between items were sufficiently 
large for PCA. Five principal components were extracted 
and, in combination, explained 68% of the variance in cog-
nitive performance (Fig. 1; Supplementary Tables 2 and 3). 
These were labelled verbal fluency (α = 0.89), emotion rec-
ognition (α = 0.82), attention (α = 0.93), working memory 
(α = 0.88) and general cognitive function (α = 0.68).
Agglomerative hierarchical cluster analysis
The resulting dataset contained statistically meaningful clus-
ters (H = 0.24). All internal validation measures and two out 
of four stability validation criteria favoured agglomerative 
hierarchical clustering with two clusters. The dendrogram 
was cut to produce two clusters and subjects were assigned 
cluster membership accordingly (Supplementary Fig. 1). 
Cluster 1 comprised 111 (42.5%) cognitively impaired 
participants while cluster 2 comprised 150 (57.5%) cogni-
tively spared participants. Linear discriminant analysis with 
tenfold repeated (100 times) cross-validation, using the 20 
original standardised cognitive scores as independent vari-
ables, confirmed that we were able to predict the cluster 
membership of new cases with a mean accuracy of 88.8%.
Cluster 1 comprised 93.3% (n = 14) of FEP individu-
als and 45.9% (n = 67) of CHR-P participants (Fig. 2). In 
European Archives of Psychiatry and Clinical Neuroscience 
1 3
addition, similar percentages of CHR-N and HC individuals 
were assigned to cluster 1 (CHR-N: 29.8%; HC: 30.2%).
Cluster comparisons at baseline
CHR-P individuals in cluster 1 displayed significantly lower 
premorbid IQ and poorer performance across all 20 cog-
nitive tests compared to those in cluster 2 (p < 0.01), with 
medium to large effect sizes (Supplementary Table 4), and 
were characterised by poorer social, role and premorbid 
functioning (p < 0.01) but not global functioning (Table 2; 
Fig. 3). Male CHR-P participants were also significantly 
more likely (p < 0.001) to be allocated to cluster 1 (47.8%) 
than cluster 2 (12.7%). After controlling for clinical symp-
toms and demographic characteristics, cluster member-
ship remained significantly associated with premorbid IQ 
(t = 2.565; p = 0.011), all 20 cognitive domains (t = 2.033 
to 7.166; p < 0.05), social functioning (t = 2.375; p = 0.019) 
and premorbid functioning (t = − 3.997; p < 0.001), but not 
role functioning (t = 1.548; p = 0.124). Furthermore, the pro-
portion of CHR-P participants meeting CAARMS criteria, 
SPI-A criteria or both did not differ between the clusters 
(p = 0.667).
Cluster comparisons and outcome prediction 
at follow‑up
CHR-P individuals in cluster 1 displayed significantly 
poorer global and social functioning at follow-up 6- and/or 
12-months later compared to those in cluster 2 (p < 0.05). 
Within the CHR-P group, poor functional outcome was also 
significantly more likely (p = 0.007) in cluster 1 (71.9%) 
compared to cluster 2 (47.7%).
In a binary logistic regression analysis, cluster mem-
bership explained 8.0% of the variance in functional 
outcome (p = 0.007, AUC = 0.625, sensitivity = 56.9% 
Table 1  Demographic, clinical and functional characteristics of the total sample (N = 261) at baseline
CHR-P clinical high-risk for psychosis, FEP first-episode psychosis, CHR-N clinical high-risk-negative, HC healthy control, CAARMS Compre-
hensive Assessment of At-Risk Mental States, SPI-A Schizophrenia Proneness Instrument, Adult version, GAF Global Assessment of Function-
ing, PAS Premorbid Adjustment Scale
a Effect sizes were eta squared (η2p) for Kruskal–Wallis H tests (small effect = 0.01, medium effect = 0.06, large effect = 0.14) and Cramer's V for 
Pearson’s chi-squared or Fisher–Freeman–Halton tests (small effect = 0.1, medium effect = 0.3, large effect = 0.5)









p Effect  sizea Post hoc  testb
Age (years), mean (SD) 21.47 (4.22) 24.40 (4.37) 22.94 (4.80) 22.42 (3.36) 0.003 η2p = 0.051 2,3,4 > 1
Sex, female n (%) 104 (71.2) 7 (46.7) 30 (63.8) 36 (67.9) 0.241 V = 0.127
Education (years), mean (SD) 15.12 (3.10) 15.25 (2.84) 16.45 (3.44) 16.47 (2.85) 0.010 η2p = 0.043 3,4 > 1
CAARMS severity, median (range) 28 (0–74) 79 (38–122) 6 (0–24) 0 (0–12)  < 0.001 η2p = 0.404 2 > 1 > 3 > 4
SPI-A severity, median (range) 7 (0–74) 15 (0–109) 0 (0–7) 0 (0–2)  < 0.001 η2p = 0.336 1,2 > 3,4
GAF, median (range) 58 (21–95) 41 (18–79) 70 (43–94) 88 (67–97)  < 0.001 η2p = 0.343 4 > 3 > 1 > 2
Social functioning (current), median 
(range)
8 (3–10) 8 (6–9) 9 (8–10)  < 0.001 η2p = 0.229 4 > 3 > 1
Role functioning (current), median (range) 8 (3–9) 8 (5–9) 9 (5–9)  < 0.001 η2p = 0.199 4 > 3 > 1
PAS average, median (range) 1.28 (0–3.43) 0.86 (0–3.86) 0.43 (0–1.64)  < 0.001 η2p = 0.189 1 > 3 > 4
Comorbidity, n (%)
 Anxiety disorder 104 (71.2) 22 (46.8) 0 (0)  < 0.001 V = 0.568 1 > 3 > 4
 Mood disorder 97 (66.4) 14 (29.8) 0 (0)  < 0.001 V = 0.552 1 > 3 > 4
 Alcohol abuse/dependence 46 (31.5) 11 (23.4) 0 (0)  < 0.001 V = 0.297 1,3 > 4
 Substance abuse/dependence 24 (16.4) 3 (6.4) 0 (0) 0.002 V = 0.221 1 > 4
 Eating disorder 13 (8.9) 1 (2.1) 0 (0) 0.023 V = 0.170 1 > 4
Psychological treatment, n (%)
 Current 25 (17.1) 5 (33.3) 5 (10.6) 0 (0) 0.002 V = 0.243 2 > 3,4 and 1 > 4
 Past 66 (45.2) 5 (33.3) 15 (31.9) 3 (5.7)  < 0.001 V = 0.323 1,2,3 > 4
Medication, n (%)
 Antidepressants 53 (36.3) 9 (60.0) 13 (27.7) 0 (0)  < 0.001 V = 0.354 2 > 3,4 and 1 > 4
 Mood stabilisers 4 (2.7) 0 (0) 0 (0) 0 (0) 0.592 V = 0.111
 Antipsychotics 4 (2.7) 7 (46.7) 0 (0) 0 (0)  < 0.001 V = 0.526 2 > 1,3,4
 Anxiolytics 10 (6.8) 5 (33.3) 1 (2.1) 0 (0)  < 0.001 V = 0.304 2 > 1,3,4
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and specificity = 68.0%). Based on the odds ratio, poor 
functional outcome was 2.81 times higher if participants 
were assigned to cluster 1 rather than cluster 2. This 
association remained significant after adjusting for GAF 
score at baseline (adjusted odds ratio = 2.52, p = 0.030). 
In contrast, cluster membership could not predict clinical 
outcomes in terms of CAARMS persistence (p = 0.768) 
or transition to psychosis (p = 0.170).
Additional analyses
The PCA and cluster analysis were repeated following 
the exclusion of the small sample of FEP participants 
to verify the stability and interpretability of our results. 
Overall, results remained unchanged, albeit with slightly 
smaller effect sizes (see Supplementary Results and Sup-
plementary Figs. 2–5).
Discussion
Using a data-driven hierarchical clustering approach in 
conjunction with PCA, we identified a two-cluster solu-
tion, comprising a cognitively spared and cognitively 
impaired subgroup, in a sample consisting of CHR-P and 
FEP participants as well as CHR-N participants and HCs. 
While the majority of FEP individuals were assigned to 
the cognitively impaired cluster, CHR-P individuals were 
almost equally distributed. At both baseline and follow-
up, CHR-P individuals classified as cognitively impaired 
displayed significantly poorer functioning than their cog-
nitively spared counterparts with cluster membership able 
to predict functional but not clinical outcome.
Fig. 1  Component loading plot for the total sample (N = 261). ATT attention, ER emotion recognition, GCF general cognitive function, VF ver-
bal fluency, WM working memory
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Hierarchical clustering on principal components
In the present study, PCA was applied prior to clustering 
to reduce data dimensionality, thereby reducing informa-
tion redundancy and maximising explanatory variance 
[61]. Verbal fluency, emotion recognition, attention, work-
ing memory and general cognitive function were the five 
principal components that explained 68% of the variance 
in cognitive performance across the entire sample. Interest-
ingly, Lam et al. [62] observed a similar cognitive compo-
nent structure in both CHR-P and HC samples, indicating 
that our components constitute reproducible dimensions of 
cognitive performance.
The emergence of a two-cluster solution is in agreement 
with previous studies involving schizophrenia-spectrum dis-
orders [14, 20, 28, 63, 64]. However, three- or four-cluster 
solutions are more typically reported in mixed samples of 
FEP and HC participants [26, 27]. Furthermore, the only 
study to investigate cognitive subgroups in CHR-P partici-
pants obtained a four-cluster solution [29]. It is possible that 
our two-cluster solution partially reflects the novel combina-
tion of FEP and CHR-P participants as well as the applica-
tion of basic symptom criteria to recruit CHR-P individu-
als. Nevertheless, this solution has resulted from replicable 
cognitive components [62], supporting the validity of our 
findings.
Finally, it is important to note that the majority of CHR-P 
participants in the current study were recruited from the com-
munity and not through dedicated clinical pathways. Commu-
nity-recruitment strategies represent an important aspect of 
early detection and intervention [65, 66]. Indeed, there may be 
a substantial number of young people at CHR-P in the com-
munity who are not seen by specialised early detection ser-
vices [65]. Therefore, community-recruitment strategies are 
Fig. 2  The distribution of a clusters within each diagnostic group and b diagnostic groups within each cluster for the total sample (N = 261). 
CHR-P clinical high-risk for psychosis, FEP first-episode psychosis, CHR-N clinical high-risk-negative; HC healthy control
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particularly advantageous in their ability to detect more rep-
resentative samples, ensuring that findings can be generalised 
to the entire population of individuals at CHR-P.
Characterising within‑group cognitive 
heterogeneity
In line with Velthorst et al. [29], our CHR-P group exhibited 
substantial cognitive heterogeneity, with 45.9% of individu-
als assigned to the cognitively impaired subgroup. On the 
other hand, cognitive heterogeneity was less apparent in 
our FEP group, contrasting with previous findings in larger 
Table 2  Demographic, clinical and functional characteristics of the CHR-P group by cognitive cluster at baseline (N = 146) and follow-up 
(N = 122)
CHR-P clinical high-risk for psychosis, CAARMS Comprehensive Assessment of At-Risk Mental State, SPI-A Schizophrenia Proneness Instru-
ment, Adult version, GAF Global Assessment of Functioning, PAS premorbid adjustment scale
a Effect sizes were Rosenthal's r for Mann–Whitney U tests and Phi (ϕ) for Pearson’s chi-squared or Fisher′s exact tests (small effect = 0.1, 
medium effect = 0.3, large effect = 0.5)
b 19 non-transitioned CHR-P individuals have yet to reach the 3-year follow-up
Baseline Cluster 1 Cluster 2 p Effect  sizea
Impaired (N = 67) Spared (N = 79)
Age (years), mean (SD) 21.36 (4.63) 21.56 (3.86) 0.288 r = 0.088
Sex, female n (%) 35 (52.2) 69 (87.3)  < 0.001 ϕ = 0.386
Education (years), mean (SD) 14.96 (3.43) 15.25 (2.80) 0.421 r = 0.067
CAARMS severity, median (range) 29 (0–74) 28 (0–72) 0.212 r = 0.103
SPI-A severity, median (range) 6 (0–61) 7 (0–74) 0.883 r = 0.012
GAF, median (range) 55 (21–87) 60 (21–95) 0.094 r = 0.139
Social functioning (current), median (range) 7 (3–10) 8 (3–10)  < 0.001 r = 0.296
Role functioning (current), median (range) 7 (4–9) 8 (3–9) 0.002 r = 0.255
PAS average, median (range) 1.36 (0–3.43) 0.86 (0–2.57)  < 0.001 r = 0.405
Comorbidity, n (%)
 Anxiety disorder 49 (73.1) 55 (69.6) 0.640 ϕ = 0.039
 Mood disorder 50 (74.6) 47 (59.5) 0.054 ϕ = 0.160
 Alcohol abuse/dependence 18 (26.9) 28 (35.4) 0.266 ϕ = 0.092
 Substance abuse/dependence 11 (16.4) 13 (16.5) 0.995 ϕ = 0.001
 Eating disorder 4 (6.0) 9 (11.4) 0.252 ϕ = 0.095
Psychological treatment, n (%)
 Current 15 (22.4) 10 (12.7) 0.120 ϕ = 0.129
 Past 27 (40.3) 39 (49.4) 0.273 ϕ = 0.091
Medication, n (%)
 Antidepressants 25 (37.3) 28 (35.4) 0.815 ϕ = 0.019
 Mood stabilisers 2 (3.0) 2 (2.5) 10.000 ϕ = 0.014
 Antipsychotics 3 (4.5) 1 (1.3) 0.333 ϕ = 0.098
 Anxiolytics 4 (6.0) 6 (7.6) 0.754 ϕ = 0.032
Baseline Cluster 1 Cluster 2 p Effect  sizea
Impaired (N = 57) Spared (N = 65)
 GAF, median (range) 52 (21–88) 68 (33–88) 0.012 r = 0.227
 Poor functional outcome, n (%) 41 (71.9) 31 (47.7) 0.007 ϕ = 0.246
 Social functioning (current), median (range) 8 (2–10) 8 (4–9) 0.021 r = 0.209
 Role functioning (current), median (range) 8 (4–9) 8 (5–9) 0.139 r = 0.134
 CAARMS severity, median (range) 15 (0–71) 12 (0–82) 0.886 r = 0.013
 CAARMS persistence, n (%) 17 (29.8) 21 (32.3) 0.768 ϕ = 0.027
  Transitionsb, n (%) 9 (15.8) 5 (7.7) 0.162 ϕ = 0.127
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samples [26, 27]. Approximately 16% fewer CHR-N par-
ticipants were classified as cognitively impaired relative to 
CHR-P participants, indicating that cognitive impairment is 
somewhat more prevalent in the CHR-P state. Interestingly, a 
considerable proportion of HCs (30.2%) were also allocated 
to the cognitively impaired subgroup, supporting previous 
findings [26]. Overall, these results support the notion of a 
cognitive continuum [12, 16, 67], at least among CHR-P, 
CHR-N and HC populations.
Cluster comparisons in the CHR‑P group
Cognitively impaired CHR-P individuals displayed signifi-
cantly poorer performance across all domains with large 
effect sizes for verbal memory, verbal fluency and attention 
and processing speed. Indeed, cognitive scores fell mostly 
within 0.5–1.0 SDs below HC data for cognitively impaired 
participants. Deficits in facial emotion recognition were also 
significantly greater in cognitively impaired individuals with 
medium effect sizes, indicating that cluster membership was 
driven by the degree of impairment across both neurocogni-
tive and social cognitive domains.
Within the CHR-P group, cognitively impaired individu-
als had significantly poorer functioning than cognitively 
spared individuals. While role functioning and global func-
tioning were significantly reduced at baseline and follow-up, 
respectively, social functioning was impaired at both time 
points, in line with previous findings [29]. Lower levels of 
premorbid functioning and premorbid IQ were also observed 
in the cognitively impaired vs. cognitively spared subgroup, 
consistent with previous studies across the psychosis spec-
trum [15, 18, 25, 27]. These findings, in addition to the larger 
number of male participants in our cognitively impaired sub-
group, may support the existence of a neurodevelopmental 
contribution towards pronounced cognitive impairments in 
CHR-P participants [68], in line with previous results in psy-
chosis patients [69].
In contrast, positive symptom severity did not signifi-
cantly differ between cognitive subgroups. Cluster analyses 
have produced mixed findings, reporting either no significant 
differences across cognitive subgroups in the schizophrenia-
spectrum [18, 25, 28, 63] or greater positive symptom sever-
ity in the most cognitively impaired cluster [12, 15, 26, 27]. 
Furthermore, the proportion of CHR-P participants meet-
ing CAARMS criteria, SPI-A criteria or both did not differ 
between the cognitive subgroups, contrasting with previous 
reports of lesser cognitive deficits in individuals meeting 
basic symptom, as opposed to UHR, criteria [70].
Outcome prediction in the CHR‑P group
Importantly, we were also able to predict functional out-
come from cluster membership, with cognitively impaired 
CHR-P individuals significantly more likely to experience 
Fig. 3  Level of functioning across cognitive clusters for the CHR-P group (N = 146)
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poor functional outcome at follow-up. Conversely, cluster 
membership was unable to predict clinical outcomes in 
terms of APS persistence or transition to psychosis. This 
contrasts with Velthorst et al. [29] whereby impaired cogni-
tion in CHR-P individuals predicted transition to psychosis. 
Nevertheless, our findings suggest that early interventions 
targeting cognition, such as cognitive remediation, should be 
tailored towards cognitively impaired CHR-P participants to 
alleviate cognitive deficits and consequently improve func-
tional outcome [71].
Limitations
Certain limitations should be considered. First, the sample 
size of FEP participants was small, limiting our ability to 
accurately characterise cognitive heterogeneity in this group. 
Furthermore, negative symptoms were not assessed in the 
current study while cognition was only assessed at base-
line. Therefore, we were unable to ascertain the full impact 
of clinical symptomatology on cluster assignment as well 
as the stability of cognitive subgroups over time. Finally, 
cluster membership explained only 8.0% of the variance in 
functional outcome. This could, in part, be explained by our 
measure of functioning. For example, the GAF scale con-
founds functioning with symptom severity, the latter being 
unrelated to functioning in the current study. Nevertheless, 
this measure was chosen over social and role functioning 
scales as these scores were mostly limited in range.
Conclusions
We employed cluster analysis to investigate cognitive sub-
groups in CHR-P participants using a community-recruit-
ment approach, social cognitive measures and functional 
outcome prediction. We identified two discrete cognitive 
subgroups and found support for considerable cognitive het-
erogeneity within the CHR-P group. Cognitively impaired 
and cognitively spared CHR-P individuals could be distin-
guished on measures of functioning at baseline and follow-
up, with cluster membership able to predict functional out-
come. These findings emphasise the key role cognition plays 
in functioning and suggest that cluster assignment is driven 
by cognitive performance, rather than clinical symptoms. In 
addition, the current findings may support the role of cogni-
tive enhancement therapies, such as cognitive remediation, 
in CHR-P individuals with impaired cognition. Indeed, data-
driven approaches such as cluster analysis could effectively 
stratify heterogenous clinical populations along dimensions 
of interest and thus represent an important step towards per-
sonalised psychiatry. Future research should attempt to rep-
licate these findings in larger samples, over longer follow-up 
periods and also investigate whether these cognitive sub-
groups are differentially associated with neurobiological 
measures, such as measures of cortical thickness and volume 
as well as electrophysiological parameters.
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